186 related articles for article (PubMed ID: 6847695)
1. Structure-activity relationship of ligands of the pyrimidine nucleoside phosphorylases.
Niedzwicki JG; el Kouni MH; Chu SH; Cha S
Biochem Pharmacol; 1983 Feb; 32(3):399-415. PubMed ID: 6847695
[TBL] [Abstract][Full Text] [Related]
2. New analogues of benzylacyclouridines, specific and potent inhibitors of uridine phosphorylase from human and mouse livers.
Naguib FN; el Kouni MH; Chu SH; Cha S
Biochem Pharmacol; 1987 Jul; 36(13):2195-201. PubMed ID: 3606636
[TBL] [Abstract][Full Text] [Related]
3. Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines.
el Kouni MH; el Kouni MM; Naguib FN
Cancer Res; 1993 Aug; 53(16):3687-93. PubMed ID: 8339277
[TBL] [Abstract][Full Text] [Related]
4. Development of inhibitors of pyrimidine metabolism.
Cha SM
Yonsei Med J; 1989 Dec; 30(4):315-26. PubMed ID: 2697111
[TBL] [Abstract][Full Text] [Related]
5. Pyrimidine acyclonucleosides, inhibitors of uridine phosphorylase.
Niedzwicki JG; el Kouni MH; Chu SH; Cha S
Biochem Pharmacol; 1981 Aug; 30(15):2097-101. PubMed ID: 7295329
[No Abstract] [Full Text] [Related]
6. Structure-activity relationship of nucleobase ligands of uridine phosphorylase from Toxoplasma gondii.
Iltzsch MH; Klenk EE
Biochem Pharmacol; 1993 Nov; 46(10):1849-58. PubMed ID: 8250971
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of uridine phosphorylase by pyrimidine nucleoside analogs and consideration of substrate binding to the enzyme based on solution conformation as seen by NMR spectroscopy.
Veres Z; Neszmélyi A; Szabolcs A; Dénes G
Eur J Biochem; 1988 Dec; 178(1):173-81. PubMed ID: 3203686
[TBL] [Abstract][Full Text] [Related]
8. 5-benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine phosphorylase.
Niedzwicki JG; Chu SH; el Kouni MH; Rowe EC; Cha S
Biochem Pharmacol; 1982 May; 31(10):1857-61. PubMed ID: 7104017
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of uridine phosphorylase from Giardia lamblia by pyrimidine analogs.
Jiménez BM; Kranz P; Lee CS; Gero AM; O'Sullivan WJ
Biochem Pharmacol; 1989 Nov; 38(21):3785-9. PubMed ID: 2597172
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of uridine phosphorylase by some pyrimidine derivatives.
Grancharov K; Mladenova J; Golovinsky E
Biochem Pharmacol; 1991 Jun; 41(11):1769-72. PubMed ID: 2043165
[No Abstract] [Full Text] [Related]
11. Structure-activity relationship of pyrimidine base analogs as ligands of orotate phosphoribosyltransferase.
Niedzwicki JG; Iltzsch MH; el Kouni MH; Cha S
Biochem Pharmacol; 1984 Aug; 33(15):2383-95. PubMed ID: 6466360
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of uridine phosphorylase from Escherichia coli by benzylacyclouridines.
Park KS; el Kouni MH; Krenitsky TA; Chu SH; Cha S
Biochem Pharmacol; 1986 Nov; 35(21):3853-5. PubMed ID: 3535805
[TBL] [Abstract][Full Text] [Related]
13. Specificity of pyrimidine nucleoside phosphorylases and the phosphorolysis of 5-fluoro-2'-deoxyuridine.
Woodman PW; Sarrif AM; Heidelberger C
Cancer Res; 1980 Mar; 40(3):507-11. PubMed ID: 6451286
[TBL] [Abstract][Full Text] [Related]
14. Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines.
Temmink OH; de Bruin M; Turksma AW; Cricca S; Laan AC; Peters GJ
Int J Biochem Cell Biol; 2007; 39(3):565-75. PubMed ID: 17098463
[TBL] [Abstract][Full Text] [Related]
15. Inhibitor properties of some 5-substituted uracil acyclonucleosides, and 2,2'-anhydrouridines versus uridine phosphorylase from E. coli and mammalian sources.
Drabikowska AK; Lissowska L; Veres Z; Shugar D
Biochem Pharmacol; 1987 Dec; 36(23):4125-8. PubMed ID: 3318842
[TBL] [Abstract][Full Text] [Related]
16. Phenylselenenyl- and phenylthio-substituted pyrimidines as inhibitors of dihydrouracil dehydrogenase and uridine phosphorylase.
Goudgaon NM; Naguib FN; el Kouni MH; Schinazi RF
J Med Chem; 1993 Dec; 36(26):4250-4. PubMed ID: 8277507
[TBL] [Abstract][Full Text] [Related]
17. Effects of modifications in the pentose moiety and conformational changes on the binding of nucleoside ligands to uridine phosphorylase from Toxoplasma gondii.
el Kouni MH; Naguib FN; Panzica RP; Otter BA; Chu SH; Gosselin G; Chu CK; Schinazi RF; Shealy YF; Goudgaon N; Ozerov AA; Ueda T; Iltzsch MH
Biochem Pharmacol; 1996 Jun; 51(12):1687-700. PubMed ID: 8687484
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of pyrimidine bases and nucleosides by pyrimidine-nucleoside phosphorylases in cultured human lymphoid cells.
Pérignon JL; Bories DM; Houllier AM; Thuillier L; Cartier PH
Biochim Biophys Acta; 1987 Apr; 928(2):130-6. PubMed ID: 3567226
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 2: optimization of inhibitors of human thymidine phosphorylase and their selectivity with uridine phosphorylase.
Yano S; Kazuno H; Sato T; Suzuki N; Emura T; Wierzba K; Yamashita J; Tada Y; Yamada Y; Fukushima M; Asao T
Bioorg Med Chem; 2004 Jul; 12(13):3443-50. PubMed ID: 15186830
[TBL] [Abstract][Full Text] [Related]
20. Irreversible enzyme inhibitors. 202. Candidate active-site-directed irreversible inhibitors of 5-fluoro-2'-deoxyuridine phosphorylase from Walker 256 rat tumor derived from 1-benzyl-5-(3-ethoxybenzyl)uracil.
Kelley JL; Baker BR
J Med Chem; 1982 May; 25(5):600-3. PubMed ID: 6211547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
